Japanese drug major Astellas Pharma (TYO: 4503) has announced the promotion of James Robinson as president, Americas operations, for Astellas US, with responsibility for the company's operations in North and South America, effective April 1, 2016.
Mr Robinson previously served as president, Astellas Pharma US, representing the commercial organization in the USA, a role he assumed in 2013. He will succeed Masao Yoshida, who is retiring in June 2016.
"As a 10-year veteran of Astellas with more than 20 years of healthcare industry experience, Jim's commitment to operational and commercial excellence has helped Astellas grow dramatically in the Americas," said Astellas Pharma Inc president and chief executive Yoshihiko Hatanaka, adding: "His deep experience, skills and strong commitment to operating and leading with the highest sense of ethics and compliance will help Astellas stay focused on our global vision to be on the forefront of healthcare change to turn innovative science into value for patients."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze